Genetic, model system, and neuropathology studies have clearly established Aβ, tau and APOE as disease hallmarks, biomarkers and therapeutic targets in AD and other neurodegenerative diseases [104–106]. This evidence concerns the gene MAPT and Alzheimer disease.